Placeholder Banner

BIO Applauds House Passage of the 21st Century Cures Act

November 30, 2016

Washington, DC (November 30, 2016) – Biotechnology Innovation Organization (BIO) President and CEO James C. Greenwood issued the following statement today regarding passage of the 21st Century Cures Act by the U.S. House of Representatives:

 “The 21st Century Cures Act passed by the House of Representatives today is an important victory for patients and for the next generation of medical innovation. The legislation advances important patient-centered policies that can speed the pace of drug development, while authorizing essential funding for scientific discovery and the promotion of biomedical advancements that can help transform healthcare for patients with the promise of next generation modern medicines.

“We applaud the work of the House for making sure that this important legislation remained a priority. We particularly want to recognize Representatives Upton, DeGette and Pallone for their tireless, bi-partisan leadership in crafting and advancing the Act. We urge the Senate to swiftly consider and pass the Act so that patients may begin to benefit from its important advances.”

Read BIO’s letter in support of the 21st Century Cures Act here.
 

Upcoming BIO Events

BIO CEO & Investor Conference
February 13-14, 2017
New York, NY

BIO International Convention
June 19-22, 2017
San Diego, CA


###

Discover More
BIO President & CEO John F. Crowley released the following statement:“A healthy and prosperous society is vitally important to the American people and to the world. The public health, economic security and our national security are best served…
“The Biotechnology Innovation Organization (BIO) applauds today's announcement from the USDA's Animal and Plant Health Inspection Service (APHIS) expanding the scope of biotechnology exemptions for modified plants under 7 CFR part 340. This…
BIO strongly supports a manufacturer’s ability to use a 340B rebate as an appropriate option to make 340B pricing available to covered entities."Manufacturers should have the choice to effectuate 340B pricing in the manner they deem most efficient…